NCT03830207

GPTKB entity

Statements (28)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 years and older
gptkbp:clinicalTrialPhase Phase 3
gptkbp:collaboratesWith ICON Clinical Research Limited
gptkbp:completedIn December 2022
gptkbp:condition gptkb:COVID-19
gptkbp:enrollment 1200
https://www.w3.org/2000/01/rdf-schema#label NCT03830207
gptkbp:intervention gptkb:PF-07321332
gptkb:Ritonavir
Parallel Assignment
gptkbp:location gptkb:Argentina
gptkb:Brazil
gptkb:Germany
gptkb:Japan
gptkb:South_Africa
gptkb:United_States
gptkbp:mask Double
gptkbp:officialName A Study of PF-07321332/Ritonavir in Nonhospitalized High-Risk Adult Participants With COVID-19
gptkbp:purpose Treatment
gptkbp:recognizedBy gptkb:NCT03830207
gptkbp:result Proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28
gptkbp:sponsor gptkb:Pfizer
gptkbp:startDate February 2019
gptkbp:status Completed
gptkbp:studyType Interventional
gptkbp:bfsParent gptkb:uveal_melanoma
gptkbp:bfsLayer 7